Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2006

View Archived Issues

Efficacy of HCD-122 in preclinical models of Hodgkin's and non-Hodgkin's lymphoma

Tanespimycin/bortezomib combination shows promise in multiple myeloma

High rate of response to romidepsin seen in cutaneous T-cell lymphoma study

JAK2 inhibitors may be useful to treat myeloproliferative disorders

Preclinical and clinical results of enzastaurin in hematologic disorders

Merck & Co.'s alphavbeta3 integrin inhibitor prevents bone loss in rat model of bone metastasis

Velcade added to NCCN treatment protocol for newly diagnosed multiple myeloma

Somanta signs letter of intent with Virium for phenylbutyrate

Oxytrex begins phase III study in subjects prone to opioid dependence

GEM OS1 as effective as autograft for the stimulation of bone healing

Preclinical data from glioblastoma models on cilengitide

Targeting several key receptors potentiates antiasthmatic effects of antisense oligonucleotides

Abbott and Enanta partner on HCV protease inhibitors

Reliant seeks to expand use of Omacor

Crucell's rabies monoclonal antibody product enters phase I study

Dainippon Sumitomo Pharma to take on overseas development of lurasidone

Tekturna review extended

Schering-Plough to acquire rights to pradefovir

Glenmark to begin phase I trials in Europe for GRC-6211

Nycomed receives E.U., U.S. regulatory clearances for Altana Pharma acquisition

Cyclacel files IND to begin clinical trials of CYC-116

European labeling agreement for Mezavant

JKB-122 set for phase II study for liver function restoration in hepatitis C patients

Positive interim results for AVN-944 in hematologic malignancies

Aloxi meets endpoints in phase III PONV trials

Novel antiinfective agents disclosed in recent F2G and Daiichi patents

Gilead scientists prepare and test novel HIV integrase inhibitors

Foradil Certihaler receives FDA approval

Non-approvable letter for Genasense in CLL

Tarceva recommended for approval in E.U. for metastatic pancreatic cancer

Regulatory advances for Thelin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...